-
-
Target Selection
-
Lead Identification & Optimization
-
Formats & Scaffolds
-
Bi/Multispecifics
-
Emerging Technologies
1-2-1 Meetings/Networking Break
1-2-1 Meetings (Salon E/G) | Networking Break (Grand Foyer)
-
Bi/Multispecifics
Salon D
Can bi- or multi-specifics approaches revitalize known targets? Balancing the target affinities and
...
-
-
Target Selection
-
Lead Identification & Optimization
-
Formats & Scaffolds
-
Bi/Multispecifics
-
Emerging Technologies
Drinks-Canape Reception
Grand Foyer
-
Emerging Technologies
Salon F
Disease complexity, e.g. causality, heterogeneity, targetability, etc Drug discovery efficiency, e.g
...
-
Lead Identification & Optimization
-
Lead Identification & Optimization
Salon B
Agonistic antibodies to checkpoint inhibitors – how to select the best epitope and achieve engagemen
...
-
Target Selection
Salon A
What does a protein engineer bring to the table when selecting therapeutic targets? What are new or
...
-
Emerging Technologies
Salon H
The computational development of antibodies is an emerging industry that has become feasible thanks
...
-
Bi/Multispecifics
Salon D
We will explore some of the cutting-edge advancements in our antibody discovery and engineering appr
...
-
Formats & Scaffolds
Salon C
Biologics have become the top-selling class of therapeutics that continue to grow as new drugs are a
...
-
Lead Identification & Optimization
-
Lead Identification & Optimization
Salon B
VHHs, the variable domains of camelid heavy chain-only antibodies, are gaining significant attention
...
-
Target Selection
Salon A
The PioneerTM Antibody Discovery Platform is Bio-Rad’s new service for biotherapeutic lead generatio
...
-
-
Target Selection
-
Lead Identification & Optimization
-
Formats & Scaffolds
-
Bi/Multispecifics
-
Emerging Technologies
Salon H
We will explore some of the cutting-edge advancements in our antibody discovery and engineering appr
...
-
-
Target Selection
-
Lead Identification & Optimization
-
Formats & Scaffolds
-
Bi/Multispecifics
-
Emerging Technologies
Salon H
Antibody fragments like Fab, ScFv, and VHH are emerging stars in antibody drug development, utilized
...
-
-
Target Selection
-
Lead Identification & Optimization
-
Formats & Scaffolds
-
Bi/Multispecifics
-
Emerging Technologies
1-2-1 Meetings/Networking Break
1-2-1 Meetings (Salon E/G) | Networking Break (Grand Foyer)
-
-
Target Selection
-
Lead Identification & Optimization
-
Formats & Scaffolds
-
Bi/Multispecifics
-
Emerging Technologies
Afternoon refreshments
Grand Foyer
-
-
Target Selection
-
Lead Identification & Optimization
-
Formats & Scaffolds
-
Bi/Multispecifics
-
Emerging Technologies
Registration
Grand Foyer
-
-
Target Selection
-
Lead Identification & Optimization
-
Formats & Scaffolds
-
Bi/Multispecifics
-
Emerging Technologies
1-2-1 Meetings/Networking Break
1-2-1 Meetings (Salon E/G) | Networking Break (Grand Foyer)
-
-
Target Selection
-
Lead Identification & Optimization
-
Formats & Scaffolds
-
Bi/Multispecifics
-
Emerging Technologies
Networking Lunch
Thomson Hall - First Floor
-
Emerging Technologies
Salon F
Antibody discovery vs complex antigens that cannot be easily purified remains a challenge. Does the
...
-
Bi/Multispecifics
Salon D
Common Light Chain discovery approaches, advantages, and limitations Single Domain Antibodies: what
...
-
Lead Identification & Optimization
-
Lead Identification & Optimization
Salon B
Integrated antibody discovery mindset based on biotherapeutic MOA is critical. How to choose lead id
...
-
-
Target Selection
-
Lead Identification & Optimization
-
Formats & Scaffolds
-
Bi/Multispecifics
-
Emerging Technologies
1-2-1 Meetings/Networking Break
1-2-1 Meetings (Salon E/G) | Networking Break (Grand Foyer)
-
-
Target Selection
-
Lead Identification & Optimization
-
Formats & Scaffolds
-
Bi/Multispecifics
-
Emerging Technologies
Morning refreshments
Grand Foyer
-
-
Target Selection
-
Lead Identification & Optimization
-
Formats & Scaffolds
-
Bi/Multispecifics
-
Emerging Technologies
1-2-1 Meetings/Networking Break
1-2-1 Meetings (Salon E/G) | Networking Break (Grand Foyer)
-
Emerging Technologies
Salon F
-
Bi/Multispecifics
Salon D
-
Lead Identification & Optimization
-
Lead Identification & Optimization
Salon B
-
Formats & Scaffolds
Salon C
-
Target Selection
Salon A
-
-
Target Selection
-
Lead Identification & Optimization
-
Formats & Scaffolds
-
Bi/Multispecifics
-
Emerging Technologies
Salon H
)
The computational development of antibodies is an emerging industry that has become feasible thanks ...![Poster Presentation: Antibody Discovery Dead Ends and New Approaches: The Power of Polyclonal Sequencing [Emerging Technologies Topic]](https://cdn.asp.events/CLIENT_HubXchan_638DBA0F_0C6E_8D3C_A444829FC0C4B73E/sites/HubXChange/media/Rapid-Novor.png/fit-in/500x9999/filters:no_upscale())
We will explore some of the cutting-edge advancements in our antibody discovery and engineering appr ...![Poster Presentation: AlivaMab' Platforms for Discovery and Engineering for Bispecifics and Advanced Modalities Jane Seagal, Vice President, Antibody Discovery, Ablexis and AlivaMab Discovery Services [Bi/ Multi Specifics Topic]](https://cdn.asp.events/CLIENT_HubXchan_638DBA0F_0C6E_8D3C_A444829FC0C4B73E/sites/HubXChange/media/libraries/experts/Ablexis-Alivamab-Stacked-Logo.png/fit-in/500x9999/filters:no_upscale())
Biologics have become the top-selling class of therapeutics that continue to grow as new drugs are a ...Poster Presentation by Ablexis and AlivaMab Discovery Services)
VHHs, the variable domains of camelid heavy chain-only antibodies, are gaining significant attention ...Poster Presentation by Immunoprecise Antibodies![Poster Presentation: Pioneer Platform: A Novel Biotherapeutic Antibody Discovery Platform [Lead Identification & Optimization Topic]](https://cdn.asp.events/CLIENT_HubXchan_638DBA0F_0C6E_8D3C_A444829FC0C4B73E/sites/HubXChange/media/libraries/partners/Bio-Rad.png/fit-in/500x9999/filters:no_upscale())
The PioneerTM Antibody Discovery Platform is Bio-Rad’s new service for biotherapeutic lead generatio ...)
We will explore some of the cutting-edge advancements in our antibody discovery and engineering appr ...)
Antibody fragments like Fab, ScFv, and VHH are emerging stars in antibody drug development, utilized ...)
Antibody discovery vs complex antigens that cannot be easily purified remains a challenge. Does the ...
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)